Mereo Biopharma Group Plc

Mereo BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for rare diseases. The company has three rare disease product candidates in its pipeline: setrusumab for the treatment of osteogenesis imperfecta (OI), partnered with Ultragenyx Pharmaceutical; alvelestat, a potential first-in-class oral therapy for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD), for which Mereo recently entered an option and license agreement with Sentynl Therapeutics (a subsidiary of Zydus Lifesciences) covering U.S. commercial and global manufacturing rights; and vantictumab for autosomal dominant osteopetrosis type 2 (ADO2), partnered with Āshibio, Inc. Mereo has retained European and UK commercial rights for both setrusumab and vantictumab, and rest-of-world commercial rights for alvelestat. The company also has exclusive global license agreements with ReproNovo SA for leflutrozole for male infertility and with Feng Biosciences for navicixizumab for late-stage ovarian cancer. Mereo trades on NASDAQ under the ticker MREO, with each ADS representing five ordinary shares. Updated Aug 11, 2026